Welcome to our dedicated page for Bolt Biotherapeutics news (Ticker: BOLT), a resource for investors and traders seeking the latest updates and insights on Bolt Biotherapeutics stock.
Bolt Biotherapeutics news coverage focuses on clinical trial data releases, regulatory milestones, and business development activities related to its cancer immunotherapy pipeline. Investors and analysts closely monitor announcements regarding the company's Boltbody Immune-Stimulating Antibody Conjugate (ISAC) platform and clinical candidates including BDC-3042 and BDC-4182.
Clinical data presentations at major oncology conferences such as the American Association for Cancer Research (AACR) Annual Meeting, the American Society of Clinical Oncology (ASCO) Annual Meeting, and the Society for Immunotherapy of Cancer (SITC) Annual Meeting generate significant news coverage. These presentations provide insights into the safety, tolerability, and preliminary efficacy of the company's drug candidates across multiple solid tumor types.
Strategic partnership announcements represent another major category of news coverage for Bolt Biotherapeutics. Collaborations with pharmaceutical companies and biotechnology firms to develop new Boltbody ISAC candidates or advance existing programs often impact investor sentiment and stock performance. These partnerships validate the platform technology and provide additional resources for clinical development.
Regulatory developments including Investigational New Drug (IND) applications, clinical trial initiations, and interactions with health authorities drive news coverage. Updates on patient enrollment milestones, dose escalation progress, and expansion cohorts in ongoing clinical trials provide visibility into development timelines and program advancement.
Financial news coverage includes quarterly earnings reports, cash runway updates, and capital raising activities. As a clinical-stage company, Bolt Biotherapeutics requires ongoing funding to support research and development activities, making financing announcements particularly relevant to investors. The company's pipeline prioritization decisions and resource allocation strategies also generate investor interest and news coverage.
Scientific publications and preclinical data releases contribute to the news landscape, particularly when they validate the mechanism of action of the Boltbody ISAC platform or demonstrate activity in new tumor types or combination therapy settings. Patent grants and intellectual property developments also receive coverage as they strengthen the company's competitive position in the immuno-oncology space.
Bolt Biotherapeutics (Nasdaq: BOLT) reported third quarter 2025 results and a business update on Nov 12, 2025. Key clinical milestone: initial clinical data for BDC-4182 Phase 1 (gastric/gastroesophageal cancer) is expected in 3Q 2026. Cash, cash equivalents, and marketable securities totaled $38.8 million as of Sept 30, 2025, and are expected to fund milestones into 2027. Third-quarter collaboration revenue was $2.2M vs. $1.1M in 3Q24. R&D expense decreased to $6.5M from $13.8M year-over-year; G&A was $3.3M. Loss from operations improved to $7.7M from $16.4M. Company presented preclinical ISAC data at SITC and continues collaborations with Genmab and Toray.
Bolt Biotherapeutics (Nasdaq: BOLT) has announced updates regarding its Phase 1 dose escalation study of BDC-4182, their next-generation Boltbody™ ISAC targeting claudin 18.2 for cancer treatment. Due to strong immune responses observed at initial dose levels, the company is modifying the clinical trial protocol to implement step-up dosing, delaying initial clinical data release to Q3 2026.
To preserve capital, Bolt is implementing a 50% workforce reduction, which will extend their cash runway into 2027. The company will maintain focus on advancing BDC-4812 clinically and supporting their ISAC collaborations to enhance shareholder value.
Bolt Biotherapeutics (Nasdaq: BOLT) reported Q2 2025 financial results and business updates. The company's lead candidate, BDC-4182, a next-generation claudin 18.2 ISAC, has entered Phase 1 dose-escalation studies for gastric and gastroesophageal cancer. The company reported $48.5 million in cash as of June 30, 2025, expected to fund operations through mid-2026.
Q2 financial highlights include collaboration revenue of $1.8 million, reduced R&D expenses of $7.5 million (down from $15.4M in Q2 2024), and G&A expenses of $3.5 million (down from $4.9M). The company completed a 1:20 reverse stock split on June 6, 2025, regaining Nasdaq compliance. Bolt continues collaborations with Genmab and Toray while seeking a partner for BDC-3042, which showed partial response in lung cancer patients.
Bolt Biotherapeutics (NASDAQ: BOLT) has announced a key opinion leader (KOL) conference call and webcast scheduled for May 12, 2025, at 2:30 p.m. PT / 5:30 p.m. ET. The event will feature Dr. Ecaterina Dumbrava from MD Anderson Cancer Center, who will discuss the Phase 1 dose-escalation clinical study results of BDC-3042 previously presented at the AACR Annual Meeting in April 2025.
During the call, Bolt's management team will also provide updates on BDC-3042 partnering plans, BDC-4182 clinical development, and first quarter 2025 financial results. A Q&A session will follow the presentations. The event will be accessible via webcast, with a replay available on the company's investor relations website.
Bolt Biotherapeutics has unveiled promising preclinical results for its next-generation Boltbody™ ISACs targeting CEA and PD-L1 at the AACR Annual Meeting 2025. The company's CEA-targeted ISAC demonstrated complete responses in mice and showed good tolerance in non-human primates (NHPs) up to 15 mg/kg.
The CEA ISAC features a novel human antibody that targets CEACAM-5, commonly found in gastrointestinal cancers. Key findings include enhanced phagocytosis of CEA-positive tumor cells and stimulation of immune-activating cytokines.
The PD-L1 ISAC showed remarkable results by:
- Directly activating and reprogramming PD-L1-expressing myeloid cells
- Achieving complete regressions in models resistant to conventional treatments
- Demonstrating favorable safety profiles in NHP studies
Both ISACs showed potential for durable responses through immunological memory, supporting their use in combination with standard-of-care therapies.
Bolt Biotherapeutics (BOLT) announced promising results from its Phase 1 dose-escalation study of BDC-3042, a novel immunotherapy for cancer treatment, at the AACR Annual Meeting 2025. The study enrolled 17 patients across seven dose cohorts with various tumor types.
Key findings include:
- BDC-3042 was well-tolerated up to 10 mg/kg q2w with no dose-limiting toxicities
- No drug-related serious adverse events or treatment discontinuations reported
- Most common drug-related adverse events: fatigue, flatulence, and nausea (12% each)
- Demonstrated favorable pharmacokinetics and biological activity
- Showed anti-tumor activity, including an unconfirmed partial response in NSCLC
- 80% of evaluable patients achieved stable disease or better
The company is now seeking partnership opportunities to advance BDC-3042's development, particularly focusing on NSCLC and post-immunotherapy settings.
Bolt Biotherapeutics (BOLT) announced it will present data from its Phase 1 dose-escalation clinical study of BDC-3042 at the AACR Annual Meeting in Chicago (April 25-30, 2025). BDC-3042 is a pioneering agonist antibody targeting dectin-2, specifically designed for patients with advanced cancers including non-small cell lung cancer (NSCLC).
The company will showcase three poster presentations: the first-in-human dose-escalation study results of BDC-3042, presented by Dr. Ecaterina Dumbrava from MD Anderson Cancer Center, and two preclinical studies featuring their Boltbody™ ISAC technology targeting CEA and PD-L1. These presentations will highlight advancements in their immunotherapy pipeline for treating various cancers including colorectal, pancreatic, and lung tumors.
Bolt Biotherapeutics (NASDAQ: BOLT) reported its Q4 and full-year 2024 financial results, highlighting key developments in its cancer immunotherapy pipeline. The company maintains a strong cash position of $70.2 million, expected to fund operations through mid-2026.
Two major programs are advancing: BDC-4182, targeting claudin 18.2 for gastric cancer, is scheduled to begin clinical trials in Q2 2025. The BDC-3042 Phase 1 trial has completed enrollment in its highest dose cohort with no dose-limiting toxicities, with results expected in Q2 2025.
Financial highlights for 2024 include: collaboration revenue of $7.7 million, R&D expenses of $57.5 million (down from $61.5M in 2023), and G&A expenses of $18.5 million (reduced from $22.5M in 2023). The company reported an operational loss of $73.0 million for the full year.
Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company focused on cancer immunotherapies, has announced its participation in two major healthcare conferences this March. The company will deliver a presentation at the TD Cowen 45th Annual Health Care Conference on March 4, 2025, at 3:10 p.m. EST. Additionally, Bolt's management team will engage in one-on-one meetings at the Leerink Partners Global Healthcare Conference on March 10, 2025.
FAQ
What is the current stock price of Bolt Biotherapeutics (BOLT)?
What is the market cap of Bolt Biotherapeutics (BOLT)?
